Medicare Restrictions On Aduhelm Do Not Signal Broad Concern With Accelerated Approvals – CMS

CMS chief medical officer Lee Fleisher addresses concerns that the Medicare national coverage determination for Alzheimer’s drugs sets a precedent for accelerated approvals. He and the FDA's Janet Woodcock also discuss prospects for closer collaboration on evidence needs pre-approval.